Get started

Stockpicks

ATNM Technical Analysis 🧙Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia. If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
AMEX:ATNMLong
by unfair_advantage
ZKIN about to hit my 300% target!As you may notice, I've posted several Stock post about this unknown NASDAQ company based in China, ZKIN. For a bit of fundamentals, checkout my first idea where the price was located at $2.00, 100% profit already! As the price of ZKIN continues to be in a strong uptrend, breaking into new recent highs, a price of $6.00 per share would be nothing unusual to see! That would lead to another 50% increase from current price and a 300% increase from my first ZKIN outlook. The weekly resistance levels are located at $4.70, $6.00 and $6.80. So a break of $4.70 can easily result in a whopping 27% increase in few days. But as the price of ZKIN likes to ride on 20 EMA, the price seems a bit overextended and a healthy correction to $3.30 area is also likely to be seen, where it may be a good idea to get into this stock! Buying dips is a good strategy in a strong uptrend, if you know where the dip will be located. MACD after a strong selling wave gave a buy signal and buying volume keeps increasing. RSI is above 60 which signifies that strong bullish momentum is present, a break below 60 will lead to a correction to $3.30 area. So either buy a break of recent high at $4.67 or buy a dip at $3.30 area. If you are looking for the best risk reward and greedy, look to buy dips at 50 EMA at $2.70 per share where the price can also be headed in a strong correction.
NASDAQ:ZKINLong
by TiborVrbovsky
3
$BNGO LONG - BEST PICK OF 2021We see very strong uptrend since December 29, stock successfully got listed on Nasdaq after maintaining position above regulations-stated price -> 1$. This stock is treasure in our hands trading for the very minimum price for now, the potential it got doesn't have borders and ranges. But according to trend lines, that make us set ranges, we can simply see +100% growth since the breakout happens in following weeks of February! And this is just the start, $BNGO can be the best investment anyone can get right now at this discounted price. Do your analysis and research before investing anywhere. Above stated ,isn't financial advice. >>>>> You can check recordings from BNGO's 5-day Next-Generation Cytogenomics Symposium, which took place from January 11 to 15 and featured 33 presentations by Saphyr users, are now available online on the company's website and its YouTube page. This event was by far its highest attended to date, with more than 15,500 session registrations and more than 6,400 session views from around the world. With the presentation recordings now available online, the impact of the event can continue to grow and expand awareness of Bionano Genomics and its Saphyr system for optical genome mapping and structural variation analysis. The event brought together scientists from leading hospitals and medical research institutions from the United States, Europe, China and Australia and covered applications of optical genome mapping (OGM) with Saphyr to study a variety of genetic diseases, blood cancers, solid tumors and repeat disorders as well as the studies supporting validation of clinical assays developed by Saphyr users. The last day of the symposium was dedicated to the study of the genomes of severely ill COVID-19 patients. Erik Holmlin, PhD, CEO of Bionano Genomics, commented: "The symposium was our most prominent showcase to date of how Saphyr comprehensively detects structural variations in a wide range of clinical and research applications. We are pleased by the enthusiasm we have seen from the scientific community around the world, and the impact of the symposium on our effort to sell Saphyr systems and access to its data through our services and reagent rental programs has been immediate. The availability of this scientific content on YouTube makes its discovery easy and continue to educate our customers on the power of Saphyr data." The recorded presentations of all speakers can be viewed their official website and on Bionano's YouTube page
NASDAQ:BNGOLong
by UnknownUnicorn10617434
4
A Buy and Forget? YJI decided to just get Yunjji at a 22% price premium, for various reasons: 1) They have a large membership, and are relatively small for a trending space for investors. 2) Look at the $BABA and $JMIA play. 3) Market cap is only $595.55M, which is relatively small. Anyways, I took a small position in it as I'm cautious, but definitely on the watchlist. That said, do your own due diligence and invest at your own risk. Everything I say is on an opinion based basis.
NASDAQ:YJLong
by gamer456148
Wait Until the $15+ Wave: Reiterating LongAgain, I think this is one of the more decent speculative plays or dip opportunities for a swing out there. Shorts are soon going to need to likely cover, you have an RSI less than 30, and people are overreacting to the clinical data and news headlines. The support level just needs to pickup for a really good squeeze. PR could come like a hammer for overly anxious bears. That said, please invest at your own risk and do your own due diligence. Everything I say is on an opinion based basis.
NASDAQ:VXRTLong
by gamer456148
GEO Technical Analysis 🧙The GEO Group Inc. is a real estate investment trust specializing in detention facilities and community-reentry centers. The company leases and oversees secure detention centers, rehabilitation and reentry facilities, and service centers for troubled youth. The GEO Group also provides counseling, education, drug abuse treatment, technology-based supervision programs, and detainee transportation. The majority of revenue comes from leasing and managing U.S. corrections & detention facilities. The GEO Group also operates in Australia, South Africa, and the United Kingdom. If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NYSE:GEOLong
by unfair_advantage
10
MAC Technical Analysis 🧙The Macerich Company is an S&P 500 company that invests in premium mall assets. The company owns 29 regional malls in its consolidated portfolio and 19 regional malls in its unconsolidated portfolio along with six power centers and six other real estate assets. The company's total portfolio has 50.6 million square feet gross leasable area and averaged $801 sales per square foot for the past 12 months, with the consolidated portfolio averaging $646 sales per square foot and the unconsolidated portfolio averaging $998 sales per square foot. If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NYSE:MACLong
by unfair_advantage
1
VYGR Technical Analysis 🧙Voyager Therapeutics Inc is functional in the United States biotechnology industry. Its focus lies in the research and development of gene therapies for the cure of severe diseases of the central nervous system such as the Parkinson's, Huntington's and Alzheimer's disease. The company has developed products such as VY-AADC01 for Advanced Parkinson's Disease, VY-HTT01 for Huntington's Disease. Voyager's sole source of revenue is generated through its collaboration with a company called Genzyme. Genzyme funds the collaboration for the multiple gene therapy programs, including programs for Parkinson's disease, Friedreich's ataxia, and Huntington's disease, as well as other CNS disorders. If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:VYGRLong
by unfair_advantage
2
$BCRX PT 23 and higher (fm @Snake Doc)BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in Phase I clinical trials to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
NASDAQ:BCRXLong
by BADQOMOCAWGOWLD
1
$ATHE is $SAVA sympathy play...Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.
NASDAQ:ATHE
by BADQOMOCAWGOWLD
My Weekly Opportunity WatchlistENVB and AEZS has positive sentiment to pickup, and some people are turning to AEZS out of excitement of a potential VXRT-like rise. DRCB is a decent entry for a long hold or a short term swing. WTI looks like it is going to go up w/ increased demand in gas and was previously oversold prior to picking up support levels. JDST will grow off of precious metals sentiment trending. Everything I'm saying is on an opinion based basis. Please invest at your own risk and do your own due diligence.
NASDAQ:ENVBLong
by gamer456148